Hippo Pathway Modulation Therapy is a novel therapeutic approach targeting the dysregulated Hippo signaling pathway in corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related 4R tauopathies. This therapy aims to restore pro-survival YAP/TAZ transcriptional activity and inhibit excessive MST1/2 activation that drives neuronal apoptosis in tau-rich environments.
The Hippo pathway has emerged as a critical regulator of neuronal survival in neurodegenerative diseases. In CBS and PSP, hyperphosphorylated tau sequesters YAP/TAZ in the cytoplasm, preventing their nuclear translocation and pro-survival transcriptional activity. Simultaneously, MST1/2 phosphorylation is increased, correlating with tau pathology burden and promoting neuronal death through caspase activation[^mst1_psp_2024].
The core Hippo pathway consists of:
In CBS and PSP tauopathies:
| Target | Mechanism | Therapeutic Approach |
|---|---|---|
| YAP/TAZ nuclear translocation | Restore pro-survival signaling | Small molecule activators |
| MST1/2 activation | Reduce apoptotic signaling | Kinase inhibitors |
| TEAD transcriptional activity | Bypass YAP/TAZ defects | TEAD agonists |
| Tau-YAP interaction | Block sequestration | Dissociation agents |
| Disease | Coverage Score | Rationale |
|---|---|---|
| CBS | 10 | Primary target - strong mechanistic evidence, Hippo pathway directly implicated |
| PSP | 9 | Similar 4R tauopathy with Hippo dysregulation |
| CBD | 10 | Core mechanism shared with CBS |
| FTD | 6 | Some tauopathy variants show Hippo involvement |
| AD | 4 | Mixed pathology, less prominent Hippo dysregulation |
| PD | 3 | Limited evidence for Hippo involvement |
| Aging | 5 | Age-related Hippo pathway changes |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | Novel mechanism not in clinical trials for CBS, distinct from tau-targeting approaches |
| Mechanistic Rationale | 9 | Strong evidence from CBS/PSP post-mortem studies showing YAP sequestration and MST1/2 activation |
| Root-Cause Coverage | 8 | Addresses neuronal survival pathway downstream of tau pathology |
| Delivery Feasibility | 7 | BBB-penetrant small molecules achievable; AAV delivery for gene therapy |
| Safety Plausibility | 7 | Off-target concerns minimal with pathway-selective agents |
| Combinability | 8 | Synergistic with tau-targeted therapies and neuroprotective approaches |
| Biomarker Availability | 6 | Nuclear YAP levels in peripheral blood cells as potential biomarker |
| De-risking Path | 7 | iPSC neuron models, then humanized mouse validation |
| Multi-disease Potential | 7 | Applicable to PSP, CBD, and other tauopathies |
| Patient Impact | 8 | Addresses core neuronal survival deficit |
Total Score: 76/100
| Milestone | Criterion |
|---|---|
| Preclinical | YAP nuclear translocation in iPSC neurons |
| Phase 1 | Safety in 12 patients |
| Phase 2A | ≥30% reduction in CSF NfL |
| Phase 2B | Clinical efficacy signal |
| Combination | Synergy Rationale |
|---|---|
| +Tau immunotherapy | Coordinate tau clearance with pro-survival signaling |
| +TFEB activator | Enhance autophagy + neuronal survival |
| +NRF2 activator | Complementary oxidative stress protection |
| +GDNF gene therapy | Coordinate neurotrophic support |